J. Goldman & CO LP Terns Pharmaceuticals, Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
A detailed history of J. Goldman & CO LP transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 235,831 shares of TERN stock, worth $870,216. This represents 0.04% of its overall portfolio holdings.
Number of Shares
235,831
Previous 203,941
15.64%
Holding current value
$870,216
Previous $1.7 Million
22.65%
% of portfolio
0.04%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding TERN
# of Institutions
160Shares Held
83.9MCall Options Held
473KPut Options Held
119K-
Soleus Capital Management, L.P. Greenwich, CT8.14MShares$30 Million3.16% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$27.9 Million1.14% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$25.4 Million7.51% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$20.6 Million1.37% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY4.75MShares$17.5 Million0.17% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $139M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...